Activity Overview
This educational activity is an archive of the live presentation held on June 10, 2026.
Target Audience
This educational program is directed toward community-based medical oncologists, hematologic oncologists, hematologists, hematopathologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the treatment of follicular lymphoma (FL).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply guideline recommendations and practice-changing advances to treatment selection in relapsed/refractory FL
- Analyze evidence for current and emerging therapeutics in the context of sequencing in FL
- Assess data from ongoing studies that impact the evolving treatment paradigms in FL
Lori A. Leslie, MD
Associate Professor of Medicine
Hackensack Meridian School of Medicine
Attending Physician, Lymphoma Division
Director, Indolent Lymphoma and CLL Research Programs
John Theurer Cancer Center
Hackensack, NJ
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, BeiGene, Genmab, Kite/Gilead, Lilly
Bachar Samra, MD
Hematology Oncology
Kelsey-Seybold Clinic
Adjunct Clinical Assistant Professor
University of Houston College of Medicine
Houston, TX
Disclosures: Advisor, Consultant, Fee for Service: AstraZeneca, Incyte Corporation, Pfizer
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.